The purpose of this study is to learn more about the effects of (classification determinant)
CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and
young adults. CD34+ stem cells are the cells that make all the types of blood cells in the
body. GVHD is a condition that results from a reaction of transplanted donor T-lymphocytes (a
kind of white blood cell) against the recipient's body and organs. Study subjects will be
offered treatment involving the use of the CliniMACS® Reagent System (Miltenyi Biotec), a
CD34+ selection device to remove T-cells from a peripheral blood stem cell transplant in
order to decrease the risk of acute and chronic GVHD.
This study involves subjects who are diagnosed with a malignant disease, that has either
failed standard therapy or is unlikely to be cured with standard non-transplant therapy, who
will receive a peripheral blood stem cell transplant. A malignant disease includes the
following: Chronic Myeloid Leukemia (CML) in chronic phase, accelerated phase or blast
crisis; Acute Myelogenous Leukemia (AML); Myelodysplastic Syndrome (MDS); Juvenile
Myelomonocytic Leukemia (JMML); Acute Lymphoblastic Leukemia (ALL); or Lymphoma (Hodgkin's
and Non-Hodgkin's).